News >

Genomic Assays Continue to Individualize Treatment for HR+ Breast Cancer

Brandon Scalea
Published: Tuesday, May 07, 2019

Sayeh Lavasani, MD, MS

Sayeh Lavasani, MD, MS

Genomic assays are painting a clearer picture of which patients with hormone receptor (HR)–positive breast cancer can receive endocrine therapy alone or do require the addition of chemotherapy, said Sayeh Lavasani, MD, MS.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication